Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

Phase 3

Completed

Conditions: Neoplasms, Breast

Interventions: Drug: Lapatinib
Drug: Trastuzumab
Drug: Aromatase Inhibitor

First Posted Date: 2010-07-12

Last Posted Date: 2025-03-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 369

Registration Number: NCT01160211

Locations: 🇬🇧
Novartis Investigative Site, Peterborough, United Kingdom

To Determine the Safety, Tolerability, Pharmacokinetics and Effect on Pain of a Single Intra-articular Administration of Canakinumab in Patients With Osteoarthritis in the Knee

Phase 2

Completed

Conditions: Osteoarthritis

Interventions: Biological: Canakinumab
Drug: Placebo to canakinumab
Drug: Placebo to Naproxen
Drug: Naproxen

First Posted Date: 2010-07-12

Last Posted Date: 2012-10-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 169

Registration Number: NCT01160822

Locations: 🇺🇸
Pinnacle Research Group, LLC, Anniston, Alabama, United States
🇺🇸
Westlake Medical Research, Westlake Village, California, United States
🇺🇸
San Diego Arthritis & Osteoporosis Medical Clinic, San Diego, California, United States

and more 6 locations

Long-term Safety Study of Vildagliptin in Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: Vildagliptin

First Posted Date: 2010-07-09

Last Posted Date: 2020-12-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 245

Registration Number: NCT01159249

Locations: 🇯🇵
Novartis Investigative Site, Fukuoka, Japan

Efficacy, Safety and Pharmacokinetics of Different Regimens of Indacaterol

Phase 2

Completed

Conditions: Persistent Asthma

Interventions: Drug: Indacaterol
Drug: Placebo to Indacaterol

First Posted Date: 2010-07-05

Last Posted Date: 2011-08-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 191

Registration Number: NCT01156844

Locations: 🇺🇸
Novartis Investigator Site, Oklahoma City, Oklahoma, United States
🇬🇧
Novartis Investigative Site, Merthyr Tydfil, United Kingdom

Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of Omalizumab in Japanese Children (6 - 15 Years)

Phase 3

Completed

Conditions: Allergic Asthma

Interventions: Drug: omalizumab

First Posted Date: 2010-07-02

Last Posted Date: 2016-11-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 51

Registration Number: NCT01155700

Locations: 🇯🇵
Novartis Investigative Site, Osaka, Japan

Bioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Cancer
Tumors
Neoplasm

Interventions: Drug: TKI258

First Posted Date: 2010-07-02

Last Posted Date: 2020-12-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 63

Registration Number: NCT01155713

Locations: 🇺🇸
University of Utah / Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
Sarah Cannon Research Institute Sarah Cannon Research Instit, Nashville, Tennessee, United States

and more 1 locations

Open-label Long Term (52 Weeks) Safety and Tolerability of Agomelatine Sublingual Tablets in Major Depressive Disorder (MDD)

Phase 3

Terminated

Conditions: Major Depressive Disorder

Interventions: Drug: AGO178

First Posted Date: 2010-07-02

Last Posted Date: 2020-12-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 837

Registration Number: NCT01156415

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
Atlanta Center for Medical Research, Atlanta, Georgia, United States
🇺🇸
Pharmacology Research Institute, Newport Beach, California, United States

and more 94 locations

A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients

Phase 1

Completed

Conditions: Advanced and Selected Solid Tumors

Interventions: Drug: BKM120
Drug: GSK1120212

First Posted Date: 2010-07-01

Last Posted Date: 2020-12-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 113

Registration Number: NCT01155453

Locations: 🇺🇸
University of Texas/MD Anderson Cancer Center Dept of MD Anderson (8), Houston, Texas, United States
🇨🇭
Novartis Investigative Site, Bellinzona, Switzerland
🇺🇸
University of California at Los Angeles Div. of Hematology/Oncology, Los Angeles, California, United States

Effect of NVA237 on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: NVA237
Drug: Placebo

First Posted Date: 2010-06-30

Last Posted Date: 2012-05-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 108

Registration Number: NCT01154127

Locations: 🇺🇸
Spartanburg Medical Research, 485 Simuel Road, Spartanburg, South Carolina, United States
🇬🇧
Novartis Investigative Site, Manchester, United Kingdom

Safety of RAD001 in Chinese Patients With Metastatic Renal Cell Cancer

Phase 1

Completed

Conditions: Metastatic Renal Cell Carcinoma

Interventions: Drug: Everolimus (RAD001)

First Posted Date: 2010-06-29

Last Posted Date: 2020-12-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 64

Registration Number: NCT01152801

Locations: 🇨🇳
Novartis Investigative Site, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy